Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 646 to 660 of 1553 results for do not do recommendations

  1. What types of information provision, including mass-media campaigns, are effective and cost effective in preventing skin cancer in the UK? What factors influence effectiveness and cost effectiveness? •Does effectiveness and cost effectiveness vary for different population groups? (Groups could be defined by gender, age, race/ethnicity, socioeconomic status or other characteristics such as lifestyle and at-risk behaviours.) • What impact do they have on knowledge, attitudes, awareness and behaviour, including any impact on physical activity levels and vitamin D-related outcomes? • What are the key factors that aid or hinder the success of these interventions or campaigns, including for different population groups? In particular, how does changing attitudes to sunbathing and tanning – and perceptions of the risk of skin cancer –influence success? Do attitudes vary for different population groups?

    Recommendation ID PH32/2 Question What types of information provision, including mass-media campaigns, are effective and cost effective

    Research recommendation
    Published
    9 June 2015

  2. Other specialist management:- What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    Recommendation ID CG184/4 Question Other specialist management:- What specialist management is effective for people whose symptoms...

    Research recommendation
    Published
    9 June 2015

  3. Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

    Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    24 January 2018
    View recommendations

    Sections for TA498

  4. Antisocial behaviour and conduct disorders in children and young people (QS59)

    This quality standard covers recognising and managing antisocial behaviour and conduct disorders in children and young people. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    17 April 2014
    View quality statements

    Sections for QS59

  5. What is the clinical and cost effectiveness of fitting amplification devices(s) in people with tinnitus who have hearing loss but no perceived hearing difficulties?

    Recommendation ID NG155/12 Question What is the clinical and cost effectiveness of fitting amplification devices(s) in people with...

    Research recommendation
    Published
    17 March 2020

  6. Impact of risk-reducing surgery:- Further research is recommended to compare psychosocial and clinical outcomes in women who choose and women who do not choose to have risk-reducing surgery. [new 2013]

    Recommendation ID CG164/5 Question Impact of risk-reducing surgery:- Further research is recommended to compare psychosocial and clinical

    Research recommendation
    Published
    9 June 2015

  7. Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

    Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults

    Technology appraisal guidance
    Published
    28 November 2012
    View recommendations

    Sections for TA266

  8. Digital technologies to support self-management of COPD: early value assessment (HTG736)

    Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.

    HealthTech guidance
    Last updated
    17 September 2025
    View recommendations

    Sections for HTG736

  9. Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.

    Technology appraisal guidance
    Published
    26 February 2025
    View recommendations

    Sections for TA1044

  10. Methotrexate and risk of hepatotoxicity:- What is the impact of methotrexate compared with other approaches to care (for example other systemic non-biological or biological treatments) on risk of significant liver disease in people with psoriasis and do risk factors such as obesity, alcohol use or diabetes alter this risk?

    Recommendation ID CG153/2 Question Methotrexate and risk of hepatotoxicity:- What is the impact of methotrexate compared with other...

    Research recommendation
    Published
    9 June 2015

  11. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

    Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA374

  12. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)

    Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    17 February 2021
    View recommendations

    Sections for TA673

  13. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1071)

    Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    19 June 2025
    View recommendations

    Sections for TA1071

  14. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.

    Technology appraisal guidance
    Published
    27 October 2010
    View recommendations

    Sections for TA204

  15. What is the clinical effectiveness of clozapine for children and young people with schizophrenia with symptoms unresponsive to antipsychotic medication and psychological treatment combined?

    Recommendation ID CG155/5 Question What is the clinical effectiveness of clozapine for children and young people with schizophrenia with

    Research recommendation
    Published
    9 June 2015